メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

抗横紋筋抗体陽性の重症筋無力症合併ニボルマブ関連壊死性ミオパチーの 例

  • Aiko Isami
  • , Ayaka Uchiyama
  • , Yuichi Shimaoka
  • , Shigeaki Suzuki
  • , Izumi Kawachi
  • , Nobuya Fujita

研究成果: Article › 査読

7   !!Link opens in a new tab 被引用数 (Scopus)

抄録

A 53-year-old man suffering from squamous cell lung cancer presented with bilateral ptosis and bulbar palsy a month after initial treatment with the immune checkpoint inhibitor nivolumab. The symptoms showed worsening from midday, suggesting myasthenia gravis (MG), although anti-AChR antibody was negative. Although no muscle weakness was detected, the CK level was elevated to 5,255 IU/l, and MRI of the thigh revealed inflammation of the bilateral rectus femoris muscle. A muscle biopsy showed signs of necrotizing myopathy with expression of sarcolemmal HLA class I and accumulation of macrophages, CD4, CD8, and CD20-positive lymphocytes. Positivity for anti-titin antibody, one of the anti-striated muscle antibodies, was evident. The patient was diagnosed as having nivolumab-related necrotizing myopathy with myasthenia gravis, an immune-related adverse event (irAE). Treatment with prednisolone rapidly ameliorated the symptoms, and the serum CK level normalized. There have been several reports of nivolumab-related myositis with MG. On the basis of the muscle pathology and antibody data, we were able to clarify that necrotizing myopathy was related to the pathogenesis of this case.

寄稿の翻訳タイトルA case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis
本文言語Japanese
ページ(範囲)431-435
ページ数5
ジャーナルClinical Neurology
巻59
号7
DOI
出版ステータスPublished - 2019

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

Keywords

  • Anti-striated muscle antibody
  • Immune-related adverse events (irAE)
  • Myasthenia gravis
  • Myopathy
  • Nivolumab

ASJC Scopus subject areas

  • 臨床神経学

フィンガープリント

「抗横紋筋抗体陽性の重症筋無力症合併ニボルマブ関連壊死性ミオパチーの 例」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル